Randomised Controlled Trial of 6-Mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgic

克罗恩病是一种影响肠道的慢性致残性疾病。虽然药物治疗是有效的，但大约50%的患者在诊断后的前5年内需要手术切除受影响的肠段。大多数患者术后复发。6-巯基嘌呤是一种有效的治疗克罗恩病的症状减少和健康的维护，但它的使用，以防止术后复发是不明确的。以前的研究规模小，回顾性或设计有缺陷。在这项多中心研究中，我们希望评估药物6-巯基嘌呤预防克罗恩病术后复发的价值。我们将使用症状复发作为主要结局指标，相关区域的内镜检查和进一步手术的需要作为次要结局指标。如果这项试验显示了药物的作用，我们将预期克罗恩病患者手术后的广泛吸收和生活质量的改善。

Crohn s disease is a chronic disabling condition affecting the bowel. Although medical treatment is effective approximately 50% of patient will need an operation to remove an affected segment of bowel over the first 5 years after diagnosis. Recurrence following surgery occurs in the majority of patients. 6-Mercaptopurine is an effective treatment for the reduction of symptoms and maintenance of well being in Crohn s disease but its use to prevent post operative recurrence is poorly defined. Previous studies have been small, retrospective or flawed in design. In this multicentre study we wish to assess the value of the drug 6-mercaptopurine to prevent recurrence of Crohn s disease following surgery. We will use the recurrence of symptoms as the primary outcome measure, with endoscopic examination of the relevant area and the need for further sugery as secondary outcome measures. If this trial were to show an effect of the drug we would anticipate a wide uptake and improved quality of life for patients with Crohn s disease following surgery.